Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease
Most Cited Paper
in Atrial Fibrillation Management and Outcomes
18 Months Post-Publication
Class of 2026
“Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/atrial-fibrillation-management-and-outcomes/2026/
Topics
Edoxaban monotherapy · Dual antithrombotic therapy · atrial fibrillation · Stable coronary artery disease · CHA2DS2-VASc score · Direct oral anticoagulants · Major bleeding · clinically relevant nonmajor bleeding · Myocardial infarction · Thromboembolic events · Unplanned urgent revascularization · Composite primary endpoint · Thromboembolic events · Antithrombotic therapy · EPIC-CAD trial
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Atrial Fibrillation Management and Outcomes Papers, Class of 2026. https://pri.pepkio.com/top-papers/atrial-fibrillation-management-and-outcomes/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459